Perrigo mentioned cautiously at JPMorgan JP Morgan said shares of Perrigo are moving higher on speculation regarding the impact from the FDA panel increasing OTC drugs. The firm said this will not be a big positive as the pharmacist will still dispense the drug in a restricted access market, and it might not even be the store brand.
Galmed and Perrigo sign agreement for aramchol API production Galmed (GLMD) has entered into a Manufacturing Services Agreement with Perrigo (PRGO) subsidiary Perrigo API Ltd. for the large-scale production of the active pharmaceutical ingredient of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.